Evidence map›Paper›PMID 42361479›Full record

ArticleEuropean journal of medicinal chemistry2026

Dual-target mu opioid-dopamine D

Khorshada Jahan, Grant Glatfelter, Julie Sanchez, Alexander D Maitland, Alessandro Bonifazi, Elizabeth Saab, Bradley M Keegan, Rana Rais, Guo-Hua Bi, Juan L Gomez and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Khorshada JahanMolecular Targets and Medications Discovery Branch, NIDA-IRP, Baltimore, MD, USA.
Grant GlatfelterDesigner Drug Research Unit, NIDA-IRP, Baltimore, MD, USA.
Julie SanchezDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham and Centre of Membrane Protein and Receptors, Universities of Birmingham and Nottingham, Nottingham, Midlands, UK.
Alexander D MaitlandDesigner Drug Research Unit, NIDA-IRP, Baltimore, MD, USA.
Alessandro BonifaziMolecular Targets and Medications Discovery Branch, NIDA-IRP, Baltimore, MD, USA; Department of Pharmacology and Toxicology, Center for Addiction Sciences and Therapeutics, University of Texas Medical Branch, Galveston, TX, USA.
Elizabeth SaabMolecular Targets and Medications Discovery Branch, NIDA-IRP, Baltimore, MD, USA.
Bradley M KeeganMolecular Targets and Medications Discovery Branch, NIDA-IRP, Baltimore, MD, USA.
Rana RaisJohns Hopkins Drug Discovery Program, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Guo-Hua BiAddiction Biology Unit, Molecular Targets and Medications Discovery Branch, NIDA-IRP, Baltimore, MD, USA.
Juan L GomezBiobehavioral Imaging and Molecular Neuropsychopharmacology Section, NIDA-IRP, Baltimore, MD, USA.
Michael MichaelidesBiobehavioral Imaging and Molecular Neuropsychopharmacology Section, NIDA-IRP, Baltimore, MD, USA.
Zheng-Xiong XiAddiction Biology Unit, Molecular Targets and Medications Discovery Branch, NIDA-IRP, Baltimore, MD, USA.
J Robert LaneDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham and Centre of Membrane Protein and Receptors, Universities of Birmingham and Nottingham, Nottingham, Midlands, UK.
Meritxell CanalsDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham and Centre of Membrane Protein and Receptors, Universities of Birmingham and Nottingham, Nottingham, Midlands, UK.
Michael H BaumannDesigner Drug Research Unit, NIDA-IRP, Baltimore, MD, USA.
Amy Hauck NewmanMolecular Targets and Medications Discovery Branch, NIDA-IRP, Baltimore, MD, USA. Electronic address: anewman@intra.nida.nih.gov.

Funding

Novel Dopamine D3 Receptor Ligands ZIADA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 2009 to 2025
$25.9M
NOVEL DOPAMINE D3 RECEPTOR LIGANDSZ01DA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 1999 to 2008
$1.8M
Development of Dual Dopamine/Serotonin Releasing AgentsZ01DA000522 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI ROTHMAN, RICHARD · 2008 to 2008
$598k
Intramural NIH HHS Z01 DA000424Intramural NIH HHS Z01 DA000522Intramural NIH HHS ZIA DA000424
6 · The paper itself

Abstract

The development of opioid analgesics with low abuse liability remains a challenge. As dopamine D

Indexed as

AnalgesicsAnalgesics, OpioidReceptors, Dopamine D3Receptors, Opioid, muAnimalsDose-Response Relationship, DrugHumansLigandsMaleMiceMice, Inbred C57BLMolecular StructureStructure-Activity RelationshipAnalgesicsAnalgesics, OpioidLigandsReceptors, Dopamine D3Receptors, Opioid, muAbuse liabilityAnalgesiaBivalent ligandsDopamine D(3) receptorsDual-target drug designEtonitazeneMu opioid receptorsOpioid use disorderRespiratory depression

Identifiers

PMID42361479
PMCPMC13334489

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.